Abilify Wins FDA Approval
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Company won FDA approval for Abilify (aripiprazole) for the treatment of acute bipolar mania, including manic and mixed episodes associated with bipolar disorder.
The company expects to join the prescription weight-loss market by 2014's third quarter.
Pew Charitable Trust's proposed conflict of interest guidelines could mean even less face time for sales reps and less industry money for CME programs.
The Boston-based agency hopes the new department will allow teams a broader perspective.